Table 1 Baseline attributes of study subjects
statin-intolerant | controls | P-value | |
|---|---|---|---|
Number | 133 | 158 | |
percent female | 36.6% | 35.5% | NS |
age (years) | 57.1 ± 12.1 | 55.9 ± 11.3 | NS |
current smoking | 20.3% | 21.8% | NS |
on treatment for diabetes | 24.3% | 19.7% | NS |
on treatment for hypertension | 43.7% | 39.2% | NS |
on treatment for hypothyroidism | 13.2% | 11.5% | NS |
serum thyrotropin (U/L) | 4.4 ± 17.3 | 2.4 ± 2.7 | NS |
serum C-reactive protein (mg/dL) | 5.0 ± 4.6 | 4.8 ± 5.7 | NS |
serum creatine kinase (U/L) | |||
- highest recorded on treatment | 621 ± 927 | 280 ± 426 | <0.0001 |
- lowest recorded off treatment | 175 ± 220 | 120 ± 120 | 0.0095 |
- elevated 5× upper normal limit | 17.7% | 2.5% | <0.0001 |
- elevated 10× upper normal limit | 5.9% | 0.6% | 0.009 |
serum asparagine transaminase (U/L) | |||
- highest recorded on treatment | 47.5 ± 32.1 | 40.9 ± 17.5 | 0.03 |
- lowest recorded off treatment | 23.8 ± 8.7 | 23.5 ± 10.6 | NS |
- elevated 3× upper normal limit | 2.9% | 0% | 0.03 |
serum alanine transfaminase (U/L) | |||
- highest recorded on treatment | 41.9 ± 26.7 | 38.1 ± 20.7 | NS |
- lowest recorded off treatment | 32.3 ± 24.5 | 27.9 ± 15.4 | NS |
- elevated 3× upper normal limit | 1.5% | 0% | NS |
hospitalized with rhabdomyolysis | 1.5% | 0% | <0.0001 |